Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a pivotal peer-reviewed journal in the fields of pharmacology and psychiatry. Established in 1986, it has garnered a prominent reputation with a 2023 impact factor placing it in the Q2 category for both Pharmacology and Psychiatry and Mental Health. With an impressive Scopus ranking of #227 in the Psychiatry and Mental Health category and #114 in Pharmacology, it serves as an essential platform for researchers seeking to disseminate critical findings on psychopharmacological interventions and their clinical efficacy. The journal’s rigorous peer-review process ensures that only high-quality research is published, making it a trusted resource for professionals and students alike. By focusing on the latest advancements and evidence-based practices, the INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY contributes significantly to the understanding of mental health treatments, fostering ongoing dialogue and innovation in the discipline.

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.